FRANK MORICH, M.D., PH.D.

Corporate Board Profile

Tech Score: 0/100

Perspective Therapeutics, Inc.

Filing Date	Source Excerpt
2023-08-22	Frank Morich, M.D., Ph.D. has been a director of the Company since February 5, 2023... The current members of the Audit Committee are Ms. Henson (Chair), Mr. Williamson and Dr. Morich... The current members of the Nominations and Corporate Governance Committee are Dr. Morich (Chair), Ms. Woods and Mr. Williamson... Board Committees and Meetings... Frank Morich, M.D., Ph.D.: Member of Board, Member of Audit Committee, Chair of Nominations and Corporate Governance Committee... During the six-month transition period ended December 31, 2022 and the fiscal year ended June 30, 2022, each non-employee director received a cash retainer of $5,000 per month... In February 2023, the Compensation Committee approved changes to the non-employee director compensation program to provide (i) $60,000 annual cash retainer; (iii) additional annual cash retainers for committee chairs equal to $15,000...
2024-04-18	Dr. Morich holds an M.D. and Ph.D. from the University of Marburg where he specialized in immunology with a focus on monoclonal antibodies. Our Board of Directors believes that Dr. Morich’s experience as a biopharmaceutical professional with more than 35 years of industry experience qualifies him to serve on our Board.

Filing Date

Source Excerpt

2023-08-22

Frank Morich, M.D., Ph.D. has been a director of the Company since February 5, 2023... The current members of the Audit Committee are Ms. Henson (Chair), Mr. Williamson and Dr. Morich... The current members of the Nominations and Corporate Governance Committee are Dr. Morich (Chair), Ms. Woods and Mr. Williamson... Board Committees and Meetings... Frank Morich, M.D., Ph.D.: Member of Board, Member of Audit Committee, Chair of Nominations and Corporate Governance Committee... During the six-month transition period ended December 31, 2022 and the fiscal year ended June 30, 2022, each non-employee director received a cash retainer of $5,000 per month... In February 2023, the Compensation Committee approved changes to the non-employee director compensation program to provide (i) $60,000 annual cash retainer; (iii) additional annual cash retainers for committee chairs equal to $15,000...

2024-04-18

Dr. Morich holds an M.D. and Ph.D. from the University of Marburg where he specialized in immunology with a focus on monoclonal antibodies. Our Board of Directors believes that Dr. Morich’s experience as a biopharmaceutical professional with more than 35 years of industry experience qualifies him to serve on our Board.

Data sourced from SEC filings. Last updated: 2025-08-30